Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.70 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL27618577 | 0.93 | ERN1 (0.62) | ERN1GPR35XDHALDH5A1ABAT | |
| SCHEMBL16838215 | 0.85 | ERN1 (0.61) | ERN1GPR35XDHALDH5A1ABAT | |
| SCHEMBL1527066 | 0.85 | ERN1 (0.61) | ERN1GPR35XDHALDH5A1ABAT | |
| SCHEMBL17368428 | 0.83 | ERN1 (0.59) | ERN1GPR35XDH | |
| SCHEMBL531403 | 0.83 | ERN1 (0.59) | ERN1GPR35XDHALDH5A1ABAT | |
| SCHEMBL14092109 | 0.83 | ERN1 (0.59) | ERN1GPR35XDHALDH5A1ABAT | |
| SCHEMBL3083253 | 0.82 | GPR35 (0.71) | ERN1GPR35 | |
| SCHEMBL31145561 | 0.82 | ERN1 (1.00) | ERN1GPR35 | |
| SCHEMBL21373883 | 0.82 | GPR35 (0.50) | ERN1GPR35 | |
| SCHEMBL311131 | 0.82 | ERN1 (1.00) | ERN1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013139931-A1 | COMPOSITION FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WITH PARKINSONIAN SYNDROMES | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2013-09-26 | — | — | WO | claimed |
| EP-3224238-B1 | NOVEL CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-08-11 | — | — | EP | disclosed |
| EP-3224238-B1 | NOVEL CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-08-11 | — | — | EP | disclosed |
| CN-112624941-A | Method for producing entacapone | 海南通用康力制药有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-107001241-B | Novel ascomycete amides | 亥姆霍兹感染研究中心有限公司 | 2020-03-27 | — | — | CN | disclosed |
| US-10519099-B2 | Cystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-12-31 | — | — | US | disclosed |
| US-10519099-B2 | Cystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-12-31 | — | — | US | disclosed |
| US-20170327458-A1 | NOVEL CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170327458-A1 | NOVEL CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170327458-A1 | NOVEL CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2017-11-16 | — | — | US | disclosed |
| WO-2004078126-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
| EP-1409481-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5254726-A | Reacting aromatic nitroaldehydes having protected hydroxyl groups with labeled fluoride ion | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF ENERGY (US) | 1993-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327458-A1 | NOVEL CYSTOBACTAMIDES | SLC7A11, CTH, CBS | ERN1 4611/4885GPR35 1055/4885XDH 1624/4885 |
| US-10519099-B2 | Cystobactamides | CTH, TST, CBS | ERN1 4761/4885GPR35 1930/4885XDH 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.